In the present study, pancreatic disorders, including pancreatitis and pancreatic cancer, were associated with DPP-4 inhibitors and GLP-1 receptor agonists, which were consistent with results obtained via analysis of the FAERS (Butler et al., 2013; Elashoff et al., 2011). This evidence concerns the gene DPP4 and pancreatitis.